JAZZ
Jazz Pharmaceuticals plc
$232.04
-2.74%
$14.6B
No data for this timeframe.
Vol
Market Cap$14.6B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (92%)
Insider Activity0B / 10S
Insider Net $-$7.4M
SEC Reports14
Recent Activity
Aug 25, 2026
fda_pdufa
PDUFA: JAZZ — zanidatamab in HER2+ 1L advanced gastroesophageal adenocarcinoma — 2026-08-25
FDA target action date 2026-08-25 for JAZZ (Jazz Pharmaceuticals plc). Drug: zanidatamab. Indication
Jun 8, 2026
SEC
Jazz Pharmaceuticals filed a DEFA14A, which is additional definitive proxy soliciting material, filed as an amendment or
DEFA14A — Impact 3/10
Jun 5, 2026
SEC
A cluster of three Jazz Pharmaceuticals insiders sold $3.32M in stock over a one-week window, including the EVP & Chief
CLUSTER — Impact 5/10
Jun 5, 2026
Event
EPIDIOLEX
Supplemental Approval — Labeling — CANNABIDIOL — SOLUTION — ORAL
Jun 3, 2026
SEC
Three Jazz Pharmaceuticals insiders sold a total of $3.32M in open-market transactions over a 7-day window, including th
CLUSTER — Impact 3/10
Jun 3, 2026
Insider
GALA RENEE D sold 600 shares
President & CEO @ $0.00 ($0.00)
Jun 1, 2026
Insider
COZADD BRUCE C sold 6,000 shares
Director @ $235.12 ($1.4M)
May 28, 2026
Insider
Mulligan Seamus sold 3,415 shares
Director @ $138.08 ($471.5K)
Price Targets
$254.58
+11.1% upside
Buy
Current $229.19
Low $196.00
Median $253.00
High $307.00
19 analysts
$196.00
$307.00
Analyst Ratings
8Strong Buy
15Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 22, 2026 | Bernstein | INITIATE | Market Perform |
| May 22, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| May 19, 2026 | UBS | UPGRADE | Neutral → Buy |
| May 6, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $6.18 ▲ +0.9% | $5.53 — $7.07 | 175% YoY | 16 |
| Next Q | $6.39 ▲ +0.7% | $5.85 — $6.81 | -21% YoY | 16 |
| Current FY | $25.39 | $24.38 — $27.51 | 203% YoY | 16 |
| Next FY | $25.58 | $22.53 — $30.25 | 1% YoY | 16 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Jazz Pharmaceuticals filed a DEFA14A, which is additional definitive proxy soliciting material, filed as an amendment or
Jun 8, 2026
BEARISH
CLUSTER
5/10
A cluster of three Jazz Pharmaceuticals insiders sold $3.32M in stock over a one-week window, including the EVP & Chief
Jun 5, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | GALA RENEE | G | $0.00 |
| Jun 1, 2026 | COZADD BRUCE | SELL | $1.4M |
| May 28, 2026 | Mulligan Seamus | M | $471.5K |
| May 28, 2026 | Mulligan Seamus | M | $0.00 |
| May 28, 2026 | Pearce Samantha | M | $756.0K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
13 unique insiders with 10 transactions. Net insider value: -$7.4M ($0.00 bought, $7.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | GALA RENEE D | President & CEO | G | 600 | $0.00 | $0.00 |
| Jun 1, 2026 | COZADD BRUCE C | Director | SELL | 6,000 | $235.12 | $1.4M |
| May 28, 2026 | Mulligan Seamus | Director | M | 3,415 | $138.08 | $471.5K |
| May 28, 2026 | Mulligan Seamus | Director | M | 3,415 | $0.00 | $0.00 |
| May 28, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | M | 6,907 | $109.45 | $756.0K |
| May 28, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | SELL | 6,907 | $235.41 | $1.6M |
| May 28, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | M | 6,907 | $0.00 | $0.00 |
| May 28, 2026 | Patil Neena M | EVP & Chief Legal Officer | SELL | 1,192 | $236.97 | $282.5K |
| May 22, 2026 | McSharry Heather Ann | Director | SELL | 2,000 | $241.00 | $482.0K |
| May 22, 2026 | Winningham Rick E | Director | SELL | 2,741 | $241.57 | $662.1K |
| May 22, 2026 | Winningham Rick E | Director | M | 3,415 | $0.00 | $0.00 |
| May 22, 2026 | Winningham Rick E | Director | M | 3,415 | $138.08 | $471.5K |
| May 1, 2026 | COZADD BRUCE C | Director | SELL | 6,000 | $203.33 | $1.2M |
| Apr 1, 2026 | COZADD BRUCE C | Director | SELL | 3,684 | $190.22 | $700.8K |
| Mar 9, 2026 | Carr Patricia | SVP, Chief Accounting Officer | SELL | 1,287 | $182.94 | $235.4K |
| Mar 5, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | F | 2,503 | $188.69 | $472.3K |
| Mar 5, 2026 | Johnson Philip L | EVP & Chief Financial Officer | F | 2,615 | $188.69 | $493.4K |
| Mar 5, 2026 | COZADD BRUCE C | Director | F | 15,114 | $188.69 | $2.9M |
| Mar 5, 2026 | Patil Neena M | EVP & Chief Legal Officer | F | 5,000 | $188.69 | $943.5K |
| Mar 5, 2026 | GALA RENEE D | President & CEO | F | 7,065 | $188.69 | $1.3M |
| Mar 5, 2026 | Carr Patricia | SVP, Chief Accounting Officer | F | 1,436 | $186.77 | $268.2K |
| Mar 5, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | F | 1,394 | $186.75 | $260.3K |
| Mar 5, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | F | 6,209 | $188.69 | $1.2M |
| Mar 3, 2026 | COZADD BRUCE C | Director | SELL | 3,159 | $186.09 | $587.8K |
| Feb 27, 2026 | RIEDEL NORBERT G | Director | M | 3,415 | $138.08 | $471.5K |
| Feb 27, 2026 | RIEDEL NORBERT G | Director | M | 3,415 | $0.00 | $0.00 |
| Feb 27, 2026 | Carr Patricia | SVP, Chief Accounting Officer | SELL | 1,117 | $190.91 | $213.2K |
| Feb 26, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | A | 9,782 | $0.00 | $0.00 |
| Feb 26, 2026 | Patil Neena M | EVP & Chief Legal Officer | M | 20,125 | $113.10 | $2.3M |
| Feb 26, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | A | 14,822 | $0.00 | $0.00 |
| Feb 26, 2026 | LOVE TED W | Director | A | 1,527 | $0.00 | $0.00 |
| Feb 26, 2026 | GALA RENEE D | President & CEO | A | 44,465 | $0.00 | $0.00 |
| Feb 26, 2026 | Johnson Philip L | EVP & Chief Financial Officer | A | 11,857 | $0.00 | $0.00 |
| Feb 26, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | A | 4,447 | $0.00 | $0.00 |
| Feb 26, 2026 | Carr Patricia | SVP, Chief Accounting Officer | A | 2,223 | $0.00 | $0.00 |
| Feb 26, 2026 | Patil Neena M | EVP & Chief Legal Officer | M | 875 | $0.00 | $0.00 |
| Feb 26, 2026 | Patil Neena M | EVP & Chief Legal Officer | M | 20,125 | $0.00 | $0.00 |
14 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 12 neutral. Avg impact: 3.6/10.
NEUTRAL
DEFA14A
3/10
Jazz Pharmaceuticals filed a DEFA14A, which is additional definitive proxy soliciting material, file
Jun 8, 2026
BEARISH
CLUSTER
5/10
A cluster of three Jazz Pharmaceuticals insiders sold $3.32M in stock over a one-week window, includ
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Three Jazz Pharmaceuticals insiders sold a total of $3.32M in open-market transactions over a 7-day
Jun 3, 2026
NEUTRAL
144
3/10
Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, filed a Form 144 on June 1, 2026, indicat
Jun 1, 2026
NEUTRAL
8-K
2/10
Director Anne O'Riordan informed Jazz Pharmaceuticals' board that she will not stand for re-election
May 29, 2026
NEUTRAL
144
2/10
Bruce C. Cozadd, an officer at Jazz Pharmaceuticals, filed a Form 144 indicating intent to sell 6,00
May 1, 2026
NEUTRAL
10-K/A
4/10
This is an amended 10-K filing for Jazz Pharmaceuticals that primarily updates Part III to include p
Apr 24, 2026
NEUTRAL
144
3/10
Bruce Cozadd, CEO of Jazz Pharmaceuticals, filed a Form 144 to propose the sale of 6,000 shares wort
Apr 1, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Jazz Pharmaceuticals over the past week includes one open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Jazz Pharmaceuticals over the past week includes one open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
A cluster of insider transactions at Jazz Pharmaceuticals over the past week includes one open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
A recent insider trading cluster at Jazz Pharmaceuticals includes a significant open-market sale by
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
Jazz Pharmaceuticals insiders executed a mix of open-market sales and non-cash equity transactions o
Mar 4, 2026
BULLISH
8-K
7/10
Jazz Pharmaceuticals reported strong 2025 financial results with $4.3 billion in revenue (+5% YoY) a
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 25 analysts: 8 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$254.58 mean target
+11.1% upside
Buy (1.63)
$196.00 Low
$307.00 High
| Metric | Value |
|---|---|
| Current Price | $229.19 |
| Target Low | $196.00 |
| Target Mean | $254.58 |
| Target Median | $253.00 |
| Target High | $307.00 |
| # Analysts | 19 |
| Recommendation | Buy (1.63) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$6.18 | $5.53 | $7.07 | 174.9% | +0.9% | 10↑ 4↓ | $1.1B | 6.3% | 16 |
| Next Q 2026-09-30 |
$6.39 | $5.85 | $6.81 | -21.4% | +0.7% | 5↑ 9↓ | $1.2B | 2.5% | 16 |
| Current FY 2026-12-31 |
$25.39 | $24.38 | $27.51 | 203.0% | +0.3% | 11↑ 3↓ | $4.5B | 5.8% | 16 |
| Next FY 2027-12-31 |
$25.58 | $22.53 | $30.25 | 0.8% | +0.3% | 10↑ 4↓ | $4.8B | 7.1% | 16 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $6.176 | |
| 7d ago | $6.179 | -0.003 |
| 30d ago | $6.121 | +0.056 |
| 60d ago | $6.024 | +0.152 |
| 90d ago | $5.908 | +0.268 |
12 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 22, 2026 | Bernstein | INITIATE | — | Market Perform |
| May 22, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| May 19, 2026 | UBS | UPGRADE | Neutral | Buy |
| May 6, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 19, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 27, 2026 | Barclays | INITIATE | — | Overweight |
| Feb 25, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 15 | 2 | 0 | 0 | 92% | |
| May 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Feb 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Jan 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 25, 2026
fda_pdufa
PDUFA: JAZZ — zanidatamab in HER2+ 1L advanced gastroesophageal adenocarcinoma — 2026-08-25
FDA target action date 2026-08-25 for JAZZ (Jazz Pharmaceuticals plc). Drug: zanidatamab. Indication: HER2+ 1L advanced gastroesophageal adenocarcinom
Jun 8, 2026
short_volume
Short Volume: JAZZ — 89.4% short (0.5M / 0.6M)
Short: 494,388 | Exempt: 421 | TRF Vol: 552,813 | Short Ratio: 89.4% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
FDA
EPIDIOLEX
Supplemental Approval — Labeling — CANNABIDIOL — SOLUTION — ORAL
Jun 4, 2026
short_volume
Short Volume: JAZZ — 81.4% short (0.5M / 0.7M)
Short: 536,728 | Exempt: 700 | TRF Vol: 659,727 | Short Ratio: 81.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: JAZZ — 66.1% short (0.5M / 0.8M)
Short: 507,353 | Exempt: 5,600 | TRF Vol: 767,451 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: JAZZ — 74.3% short (0.6M / 0.8M)
Short: 605,319 | Exempt: 17,890 | TRF Vol: 815,231 | Short Ratio: 74.3% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: JAZZ — 80.2% short (0.6M / 0.8M)
Short: 607,877 | Exempt: 1,095 | TRF Vol: 757,754 | Short Ratio: 80.2% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: JAZZ — 1.2M shares, 39,327 trades
Week starting 2026-05-18. Total ATS volume: 1,226,281 shares across 39,327 trades.
May 15, 2026
short_volume
Short Volume: JAZZ — 77.3% short (0.6M / 0.7M)
Short: 566,368 | Exempt: 0 | TRF Vol: 732,693 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: JAZZ — 1.4M shares, 38,552 trades
Week starting 2026-05-11. Total ATS volume: 1,420,016 shares across 38,552 trades.
May 8, 2026
short_interest
FTD: JAZZ — 2,466 shares ($0.6M) failed to deliver
Settlement: 20260508, Price: $226.96, FTD Value: $559,683.36, JAZZ PHARMACEUTICALS PLC COM S
May 6, 2026
short_interest
FTD: JAZZ — 19,376 shares ($4.1M) failed to deliver
Settlement: 20260506, Price: $212.26, FTD Value: $4,112,749.76, JAZZ PHARMACEUTICALS PLC COM S
May 5, 2026
short_volume
Short Volume: JAZZ — 72.1% short (0.4M / 0.5M)
Short: 387,875 | Exempt: 30,424 | TRF Vol: 538,087 | Short Ratio: 72.1% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
JAZZ Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
Clinical Trial
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Zanidatamab (Phase 3)
Trial: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastri
May 4, 2026
dark_pool
Dark Pool: JAZZ — 2.1M shares, 47,712 trades
Week starting 2026-05-04. Total ATS volume: 2,078,320 shares across 47,712 trades.
Jun 15, 2020
FDA
ZEPZELCA